Jan 25 (Reuters) - Five Prime Therapeutics Inc:
* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE
* FIVE PRIME THERAPEUTICS INC SAYS MILESTONE WAS TRIGGERED BY INITIATION OF A MULTI-ARM PHASE 2 CLINICAL TRIAL SPONSORED BY BRISTOL-MYERS SQUIBB Source text for Eikon: Further company coverage:
 